Cochrane · systematic review · CD006884
Methotrexate for maintenance of remission in Crohn's disease
Patel, V, Wang, Y, MacDonald, JK, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 20%Low 2 · 40%Moderate 2 · 40%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Methotrexate compared to placebo for maintenance of remission in Crohn's disease
Population: patients with quiescent Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of patients maintaining clinical remission Methotrexate vs placebo | RR 1.57 [1.1, 2.23] | 2 studies · 98 participants | Moderate Downgraded: imprecision |
Proportion of patients maintaining clinical remission (high dose intramuscular methotrexate 15 mg/week) Methotrexate vs placebo | RR 1.67 [1.05, 2.67] | 1 study · 76 participants | Moderate Downgraded: imprecision |
Proportion of patients maintaining clinical remission (low dose oral methotrexate 12.5 mg/week) Methotrexate vs placebo | RR 1.35 [0.86, 2.12] | 1 study · 22 participants | Low Downgraded: imprecision |
Methotrexate compared to 6‐mercaptopurine for maintenance of remission in Crohn's disease
Population: patients with quiescent Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of patients maintaining clinical remission Methotrexate vs 6‐mercaptopurine | RR 1.36 [0.92, 2] | 2 studies · 50 participants | Very low Downgraded: risk of bias, imprecision |
Methotrexate + infliximab compared to Infliximab +/‐ placebo for maintenance of remission in Crohn's disease
Population: patients with maintenance of remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of patients maintaining remission Methotrexate + infliximab vs Infliximab +/‐ placebo | RR 1.02 [0.76, 1.38] | 2 studies · 145 participants | Low Downgraded: imprecision |